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Due to the widespread prevalence of resistant parasites, chloroquine (CQ) was removed from front-line
antimalarial chemotherapy in the 1990s despite its initial promise of disease eradication. Since then,
resistance-conferring mutations have been identified in transporters such as the PfCRT, that allow for the
efflux of CQ from its primary site of action, the parasite digestive vacuole. Chemosensitizing/
chemoreversing compounds interfere with the function of these transporters thereby sensitizing parasites to
CQ once again. However, compounds identified thus far have disappointing in vivo efficacy and screening
for alternative candidates is required to revive this strategy. In this study, we propose a simple and direct
means to rapidly screen for such compounds using a fluorescent-tagged CQmolecule.When this screen was
applied to a small library, seven novel chemosensitizers (octoclothepin, methiothepin, metergoline,
loperamide, chlorprothixene, L-703,606 and mibefradil) were quickly elucidated, including two which
showed greater potency than the classical chemosensitizers verapamil and desipramine.
W
ith the widespread distribution of drug and multi-drug resistant malaria parasites1 and the recent
emergence of artemisinin-delayed clearance P. falciparum2, research into novel antimalarial
approaches remains integral in the fight against this global disease. Although the recent discovery
of spiroindolones as potential antimalarials holds great promise3, the cost of testing and developing such new
chemical entities often restricts their numbers. Commendable initiatives have been made to fund new drug
developments but the ‘‘out-dating’’ of drugs side-lined by resistant parasites is a bitter pill to swallow.
When resistance to a drug arises due to mutations in its biological target, as exemplified by atovaquone where
changes in the cytochrome bc1-complex reduces drug-target affinity4, such drugs may only be useful in combina-
tional therapy5. For resistance due to delayed clearance, as exemplified by artemisinin resistant parasites2, it seems
conceivable to change the drug’s disposition by altering the dosing regimen, formulation or chemical structure.
This would reduce its elimination from the body and thereby prolong the duration of therapeutic blood con-
centrations of the drug. With transporter-mediated resistance, as in the case with chloroquine (CQ) resistance,
augmentation of blood concentrations by adjusting drug disposition may also be effective if the kinetics is
favourable and toxicity tolerable6. Another strategy to tackle transporter-mediated resistance is the co-admin-
istration of drugs that specifically inhibit these transporters or pumps. Indeed, the effectiveness of such chemo-
sensitizing compounds in vitro has been long-known in the case of CQ resistance (CQR) in P. falciparum5,7.
Though CQ once held the promise of being able to eradicatemalaria, its massive use (andmisuse) has led to the
emergence of CQR P. falciparum parasites8. Their rapid and almost global spread has dampened the clinical
usefulness of the drug, relegating it almost exclusively to the treatment of P. vivax, and even that use is being
challenged by the emergence of CQR P. vivax9.
While numerous chemosensitizing compounds have been painstakingly identified in the hope of restoring the
clinical usefulness of CQ, most of these display disappointing in vivo pharmacodynamics (poor potency owing to
serum protein-binding10,11, poor pharmacokinetic properties such as rapid conversion into an inactive metabo-
lite5) or have a poor safety profile and have been contraindicated against existing antimalarials12. The only
chemosensitizer that has undergone clinical trials is chlorpheniramine13, and even then, research on its efficacy
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is scarce and the results disappointing. There is a clear need to
identify novel ‘druggable’ candidates with suitable safety profiles
and in vivo efficacy in an expedient manner.
In this study, we present a novel, direct, rapid and simple screening
method to identify chemosensitizing compounds based on a new
fluorophore-tagged CQ tool. Based on the increased fluorescence
corresponding to the accumulation of this molecule in resistant para-
sites, we were able to differentiate between compounds that interfere
with CQ resistance transporters from those that do not. After optim-
ization of the assay, the screen was applied to a library of 1280
pharmacologically active compounds (LOPAC) and the validated
hits are discussed in this report.
Results
Pre-screening validation of coumarin-tagged CQ (CM-CQ). The
pfcrt gene encodes for a putative amino acid transporter that is
localized to the digestive vacuole membrane of the parasite and has
been shown to be a major modulator of chloroquine resistance14. CQ
resistant parasites accumulate less CQ than sensitive parasites via an
efflux mechanism conferred by mutations in this gene15. As such, it
was hypothesized that the accumulation of CM-CQ in resistant
parasites would be similarly reduced but might be increased in the
presence of chemosensitizers that inhibit the efflux of the drug.
To determine the functionality of CM-CQ in the identification of
chemosensitizers, seven reported chemosensitizers12 were assayed
for their effectiveness in CQ-resistant (CQR) K1 parasites. After
10 hrs co-treatment with CM-CQ and various concentrations of
these compounds, flow cytometric analysis was carried out to deter-
mine if there was a detectable increase in CM-CQ fluorescence.
Except for propranolol (PPL) and diltiazem (DTZ), there was a sig-
nificant increase in the proportion of CM-CQ-positive K1 parasites
when treated with verapamil (VPM), chlorpromazine (CPZ) and
desipramine (DSP) at 5 mM and 10 mM (P, 0.001 for all) and also
for promethazine (PMZ) and chlorpheniramine (CPR) at 10 mM
(P , 0.001 and P , 0.05 respectively) (Fig. 1a and b). The concen-
tration of chemosensitizers was set at 10 mM in subsequent screen-
ings to reduce the incidence of false negatives.
The strictly standardized mean difference (SSMD) for this assay
was calculated to be 5.87, a score suggesting that this would make an
‘‘excellent’’ screening tool with 10 mM VPM as a positive control.
However, the lack of a high-throughput cytometer led us to consider
using fluorescence-plate measurements to detect the changes in CM-
CQ accumulation instead.
To ensure the suitability of the fluorescence plate reader, the same
staining procedure was repeated with the five chemosensitizers
which showed a significant increase in CM-CQ fluorescence by flow
cytometry, and these also demonstrated a significant increase in
relative fluorescence intensity as determined by the plate reader
(Fig. 1c). Although less robust than using flow cytometry, the
SSMD for the plate readings was calculated to be 2.81, indicating
that this was a ‘‘good’’ assay with 10 mM VPM acting as control.
Additionally, VPM, CPZ and DSP were tested for their ability to
increase CM-CQ accumulation in CQ-sensitive (CQS) 3D7 and CQ-
intermediate resistance (CQIR) 7G8 parasites. The high fluorescence
levels in 3D7 compared to 7 G8 and K1 suggest that the drug is
behaving like its parent molecule (unlabelled CQ) in showing
reduced accumulation in parasites harboring the mutant PfCRT
(Fig. 1d). While none of these compounds significantly augmented
the fluorescence readings of 3D7 parasites, an increase was observed
in 7G8 after co-incubation with CPZ (P, 0.05) and DSP (P, 0.01)
but not with VPM (Fig. 1d). This is in line with literature that has
demonstrated the reduced sensitivity of 7 G8 parasites to VPM che-
mosensitization11. Having sufficiently validated the assay’s per-
formance, we proceeded to screen the LOPAC library for novel
chemosensitizers.
Screening of LOPAC Library and Hit Selection. The entire library
(supplied on sixteen 96-well plates) was screened five times and hits
were selected that were at least the mean of VPM positive controls in
each plate plus one standard deviation (X Positive Control 1 1SD). Out
of the 1280 compounds in the LOPAC library, 46 tested positive in at
least three of the five screens (Supplementary Table 1).
Two separate screens were then performed (with 10 mMof library
compounds and 6 mM of unlabelled CQ) to detect for false-positive
hits that possessed inherent fluorescence. Hits that surfaced in either
of these auto-fluorescence screens were discarded leaving only
16 hits (Supplementary Table 2). Of these, a further two were dis-
carded: compoundWIN62577 was discarded because it had unchar-
acteristically high fluorescence measurements; also, chlorpromazine
because it was already used in the optimization of the screen.
Validation of primary hits. To ensure that results were free from
contamination or mix-up during the full-library screen, individual
samples of hit compounds were purchased directly for subsequent
validation. Due to product discontinuation, clemastine fumarate was
omitted from further validation leaving only 13 hits for validation.
Flow cytometry was used to confirm the increase in CM-CQ fluor-
escence in hit-sensitized K1, and 10 of the 13 hits were validated as
having significantly increased the proportion of CM-CQ-positive
parasites (Fig. 2, P, 0.001 for cyproheptadine, loperamide,metergo-
line, L765314, L703606, mibefradil and xanthine amine; P, 0.01 for
prochlorperazine and chlorprothixene; P , 0.05 for methiothepin).
It was also demonstrated that CM-CQ accumulation was not aug-
mented in CQS 3D7 parasites treated with the same compounds
(Supplementary Figure 1). Flow cytometry was also performed to
determine if these compounds were auto-fluorescent (Supple-
mentary Figure 2a and 2b). It was shown that L765314 had a higher
level of background fluorescence in both 3D7 andK1 (P, 0.001) and
prochlorperazine had a higher background level in 3D7 only (P ,
0.05). On the basis that their fluorescence levels were not excessively
high, we decided to continue with the validation of these hits.
To exclude the interference of a compound’s possible intrinsic
antimalarial activity from its bona fide chemosensitizing effect, the
approximate IC50 of all compounds against K1 were determined by
plotting a 12-point curve (Table 1). Based on these values, the
potency of each hit in reducing CQ IC50 in K1 was assayed up to
50% of each hit’s IC50 or 10,000 nM, whichever was lower. The
modulation of CQ IC50 was indicated by a response modification
index (RMI) that has been developed by others11. Of the 13 com-
pounds, four compounds (cyclosporin A, xanthine amine, tamoxifen
and L765314) did not appear to modulate CQ IC50 even at 1 mM
(Fig. 3). In the case of xanthine amine and L765314, these hits were
probably false-positive due to their earlier noted inherent fluor-
escence (Supplementary Figure 2 and Supplementary Table 2
respectively). Four compounds, octoclothepin, methiothepin, meter-
goline and loperamide, appeared to have a moderate effect on redu-
cing CQ IC50 while another three compounds, prochlorperazine,
chlorprothixene and cyproheptadine, appear to have potencies sim-
ilar to the VPM and DSP controls. Notably, L703606 and mibefradil
appear to have superior potencies to the classical chemosensitizers,
considerably reducing CQ IC50 even at concentrations below
100 nM. A summary of the potency of all 13 compounds (described
by their corresponding EC50), their novelty as chemosensitizers and
current applications are summarized in Table 1.
Focussing only on the two most potent hits, more accurate IC50
values for mibefradil and L703606 in K1 were established with a 96-
point IC50 curve to be 108 nM and 529 nM respectively (Supple
Fig. 3). In order to be stringent in excluding the effect of their
intrinsic antimalarial activities, only a quarter of these concentra-
tions (27 nM and 132 nM respectively) were used on subsequent
validation experiments on multiple lab strains/field isolates.
www.nature.com/scientificreports
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Both compounds had negligible effects on the CQ IC50 of CQS
3D7 and HB3 and CQIR 7G8 (Fig. 4a and Supplementary Table 3).
However, both compounds reduced the CQ IC50 values of all tested
CQR parasites significantly (P, 0.05 for all). Compared to the DSP
control, L703606 was similarly effective against 8 of 8 CQR parasites,
while mibefradil was only as effective as DSP in 3 of 8 CQR parasites.
As an alternative means of assessing the two hits, their ability to half
the CQ IC50 value in the tested strains/isolates was evaluated
(Fig. 4b). Once again, L703606 was able to achieve a RMI below
0.5 for all 8 of 8 CQR parasites while mibefradil only accomplished
this in 3 of 8 of the tested strains/isolates, suggesting that L703606 is
more suitable than mibefradil as a chemosensitizer owing to its
widespread efficacy.
Discussion
Traditionally, the discovery of chemosensitizing activity has relied
heavily on the detection of changes in CQ IC50 values or isobologram
analysis. Such assays have routinely been performed by tedious
microscopic examination of Giemsa-stained slides or radioactive
assays, such as the hypoxanthine incorporation assay to measure
parasite development16. Although the utility of fluorescent nucleic
acid stains (like dihydroethidium, Hoechst33342 and SYBR Green
I16,17) and the availability of detection tools (like fluorescence plate
readers and flow cytometers) has made IC50 determination less tedi-
ous, the screening for chemosensitizers remains hampered by the
sheer number of drug dilutions that need to be made and the con-
sequential number of wells that need to be read. In this study, we
Figure 1 | Optimization of chemosensitizer detection assay. (a) Representative flow cytometry histogram overlay of K1-infected erythrocytes (at 11.3%
parasitemia) treated with 6 mM of CM-CQ and co-incubated with either vehicle control (Veh), 10 mM of propranolol (PPL) or 10 mM of verapamil
(VPM) for 10 hrs. Total percentages of positively-stained erythrocytes in R2 are shown, with the relative proportion of parasite-infected cells indicated in
brackets. (b) Proportion of CM-CQ-positive K1 parasites after co-incubation with between 0–10,000 nM of verapamil (VPM), propranolol (PPL),
diltiazem (DTZ), chlorpromazine (CPZ), desipramine (DSP), promethazine (PMZ) and chlorpheniramine (CPR). (**, P , 0.001 and *, P , 0.05
compared to negative control) Figures show mean 6 SEMs; n 5 3. (c) Fluorescence plate measurements of 3D7 (CQ-sensitive) or K1 (CQ-resistant)
cultures treated with CM-CQ in the absence or presence of 10 mM verapamil (VPM), propranolol (PPL), diltiazem (DTZ), chlorpromazine (CPZ),
desipramine (DSP), promethazine (PMZ) and chlorpheniramine (CPR). (***, P, 0.001; **, P, 0.01 and *, P, 0.05 compared to negative control)
Figures showmean6 SEMs; n5 3. (d) Fluorescence plate measurements of 3D7 (CQ-sensitive), 7G8 (CQ-intermediate resistance) or K1 (CQ-resistant)
cultures treated with CM-CQ in the absence or presence of 10 mM verapamil (VPM), chlorpromazine (CPZ) or desipramine (DSP). (***, P , 0.001;
**, P , 0.01 and *, P , 0.05 compared to negative control) Figures show mean 6 SEM; n 5 4.
www.nature.com/scientificreports
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present a novel, simple and rapid method of screening for new CQ
chemosensitizers. To validate the assay, a preliminary screen on the
LOPAC library was performed, which subsequently uncovered seven
novel chemosensitizers with pre-established drug-like properties.
By utilizing a newly-developed, fluorescent-labelled CQ tool18,19,
we have developed screening assays to quickly, easily and directly
detect changes in the uptake and retention of CQ within CQR K1
parasites. Since CQR parasites possess transporters like the CQ-res-
istance transporter (PfCRT) and p-glycoprotein homolog 1 (Pgh-1),
these transporters are believed to efflux the protonated form of
CQ from the parasite’s digestive vacuole, the drug’s primary site
of action, thereby giving rise to a low fluorescence reading.
Chemosensitizing compounds block these transporters and increase
the concentration of CQ within the parasite12 leading to an increase
in fluorescence readings. Though this difference in fluorescence
levels can bemeasured though flow cytometry sensitively, limitations
in throughput led us to utilize a fluorescent plate reader instead.
While chemosensitizers are generally believed to function
by interfering with the PfCRT, our assay is not designed to be
target-specific. Whether via interference with PfCRT, Pgh-1,
multi-drug resistance protein (PfMRP) or other transporters12, it is
the net increase in CM-CQ concentration that is being used to detect
the actual functional hits. This detection however, does not discount
the possibility of alternative mechanisms for CM-CQ accumulation:
beyond transporter interference, compounds which facilitate the
import of CM-CQ into the parasite or increase the acidity of the
DV leading to greater levels of CM-CQ retention20–22 would also be
detected. Though this lack of specificity may lead to questions about
the precisemolecular target of any hits generated, it does allow for the
identification of compounds that have the correct functional prop-
erties to achieve an increase of CM-CQ accumulation in whole-cell
environments. The elucidation of the various possible mechanisms
would be clearly the subject of further detailed studies.
After excluding for auto-fluorescent compounds and validating
the effect of the compounds in enhancing CM-CQ accumulation
in K1 via flow cytometry, further efforts were made to ensure that
the effect on altering the CQ IC50 was primarily a result of the
compounds’ chemosensitizing effect and not a synergistic effect.
Figure 2 | Confirmation of screening hits via flow cytometry. Proportion of CM-CQ-positive K1 parasites after treatment with 6 mM of CM-CQ and
10 mM of verapamil, desipramine, chlorpromazine, cyproheptadine, prochlorperazine, chlorprothixene, cyclosporine A, loperamide, metergoline,
L765314, L703606, mibefradil, methiothepin, octoclothepin, tamoxifen, xanthine amine or vehicle control (Veh). (***, P , 0.001; **, P , 0.01 and
* P 5 0.05) Figures show mean 6 SEM; n 5 3.
Table 1 |
Relative Potency Compound
Approx. IC50
for K1 (nM) Novel Phamacophore Grouping Comments
Negligible Cyclosporin A 61.2 — — Immunosuppressant, known antimalarial effect
Xanthine Amine .10,000 — — Adenosine receptor antagonist
Tamoxifen .10,000 — — Estrogen receptor antagonist
L765314 2,969 — — Adrenergic receptor antagonist
Moderate Octoclothepin .10,000 Yes Tricyclic antidepressant? Dopamine and serotonin receptor antagonist
Methiothepin 8,358 Yes Tricyclic antidepressant? Serotonin receptor antagonist
Metergoline 4,121 Yes Tricyclic antidepressant? Dopamine and serotonin receptor antagonist,
analgesic, antipyretic
Strong Loperamide 808 Yes ? Opioid receptor agonist, anti-diarrhea
Verapamil .10,000 No Calcium channel blocker Calcium channel blocker, established chemosensitizer
Prochlorperazine 4,608 No Calmodulin inhibitor Dopamine receptor antagonist, antiemetic, established
chemosensitizer
Chlorprothixene 7,173 Yes Tricyclic antidepressant? Dopamine receptor antagonist, antipsychotic drug,
known antimalarial effect
Cyproheptadine 7,314 No Histamine (H-1) receptor
antagonist
Histamine and serotonin receptor antagonist,
established chemosensitizer
Desipramine .10,000 No Tricyclic antidepressant Established chemosensitizer
Very Strong L703606 944 Yes ? Non-peptide NK-1 tachykinin receptor antagonist
Mibefradil 83 Yes? Calcium channel blocker? Non-selective calcium channel blocker
www.nature.com/scientificreports
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This was achieved by performing a dose-dependent potency study,
limited to only half the IC50 value of the hit. As a result, seven novel
chemosensitizers of varying potencies were validated and these dis-
played overall structural similarity to other known chemosensitizers.
A three-dimensional QSAR pharmacophore model for CQ-resist-
ance chemosensitizers has previously been characterized23 using the
CATALYST software from SPARTAN based on a training set of 17
compounds including imipramine and its analogues. This model
describes two aromatic hydrophobic interaction sites and a hydrogen
bond acceptor site at a side chain, preferably a nitrogen atom (Fig. 5,
top). The distances between these features are not always conserved,
but the secondary or tertiary aliphatic nitrogen atom is linked to the
aromatic rings by a two or three carbon side-chain for most of the
examples.
The seven novel chemosensitizers described in this report also
possess similar characteristics (Fig. 5, bottom) with some minor
differences. With mibefradil, the distance between the fluoro-
aromatic system and the nitrogen atom is four carbon atoms. For
L-703,606, the three aromatic rings and two nitrogen atoms mean
that several combinations are possible for the role of the two hydro-
phobic interaction sites and the hydrogen bond acceptor. Similarly,
loperamide also possesses two nitrogen atoms and three aromatic
rings, but the amide-nitrogen is less likely to play the role of the
hydrogen bond acceptor. Chlorprothixene is structurally similar to
imipramine, thus having the same distance of the aromatic hydro-
phobic interaction sites to the nitrogen atom. The structure of meter-
goline is more complex yet bearing all the salient features of the
pharmacophore. For this compound, the basic centre in the polycycle
is probably the better hydrogen bond acceptor, compared to the
carbamate group. Methiothepin and octoclothepin also conform to
the pharmacophore and differ from each other only in the substitu-
ent on the C8 position (methylthio and chloro, respectively).
Of these seven novel chemosensitizers, only L703606 and mibe-
fradil were observed to be considerably more potent than classical
chemosensitizers. Unlike the classical chemosensitizers VPM and
DSP which required concentrations of about 291 nM and 152 nM
respectively to halve the IC50 of CQ in K1, L703606 and mibefradil
required only about 98 nM and 38 nM, respectively.
L703606 is a potent and selective non-peptide neurokinin-1 (NK1)
tachykinin receptor antagonist24 but little is known about its phar-
macokinetics or toxicity profile. Mibefradil is a long-acting calcium
antagonist used in the treatment of hypertension and chronic stable
angina pectoris25. More recently, and independent to our current
findings, the synergistic antimalarial effect of mibefradil with CQ
has been identified, though its effect as a chemosensitizer was not
determined26. As a reference point, the pharmacokinetics of a single
oral 320 mg dose is briefly as follows: Cmax is about 2700 nM, Tmax is
about 2 hrs and TK is about 16 hrs25. However, due to inhibition of
the CYP3A4 pathway, numerous clinically relevant drug interactions
were predicted and this led to its voluntary withdrawal from the
market. Since mibefradil appears to be effective in K1 at below
100 nM, it is tempting to propose mibefradil as a chemosensitizing
candidate. However, it should be noted that CYP3A4 is important in
the metabolism of many antimalarial drugs27 and future clinical
studies involving the combination of antimalarial drugs with poten-
tial CYP3A4 inhibitors should proceed cautiously.
As a final round of validation, the effectiveness of L703606 and
mibefradil to sensitize multiple CQR laboratory and field isolates
were assayed at minimally toxic levels ofJ their IC50. While mibe-
fradil was more potent than L703606 in K1, its effectiveness was not
consistent across the tested parasite strains isolates. Although a
higher level of mibefradil might compensate for this discrepancy,
such heterogeneitymay be suggestive of existing genotypic variations
that modulate susceptibility to mibefradil chemosensitization. In
turn, this suggestion raises concerns about the long-term clinical
usefulness of mibefradil as a chemosensitizer. In contrast, the effec-
tiveness of L703606 was consistent in all CQR strains, suggesting that
no existing resistance traits appear to exist. This potency even in
artemisinin-resistant SMRU0233 and SMRU0272 field isolates is
indicative of the clinical relevance of L703606. However, further
studies are needed to determine if selection pressure would readily
give rise to resistant mutants.
Although assaying for the effectiveness of mibefradil and L703606
in murine models of malaria would be the next logical step, the
mechanism of CQ-resistance for murine parasites remains to be well
characterized and may or may not be similar to P. falciparum. For
example, CQ-resistant P. chabaudi mutants selected by drug-pres-
sure had no mutations in their respective orthologs of pfcrt and
pfmdr128. In P. berghei recombinant clones expressing the PfCRT
fromCQIR 7G8, the transporter was shown to be correctly expressed
and localized to theDV of parasites but failed to confer CQ resistance
ex vivo or in vivo29. In P. yoelii, innate CQ-resistance has long been
known to exist in wild-type parasites without prior drug pressure but
mechanisms of resistance have yet to be well understood. More
recently however, a study using a novel high-resolution quantita-
tive whole-genome re-sequencing approach revealed four point
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mutations on three other genes that were predicted to confer CQ
resistance in P. chabaudi30. Of these, a mutation in aat1, a putative
amino acid transporter, was shown to be crucial for resistance and
has many similarities with resistance-conferring PfCRT mutations
such as a shifting of the negative charge away from the start of the
first transmembrane helix. Though themechanisms of CQ resistance
in mice models may yet to be clear, such models have been success-
fully used to validate some chemosensitizers31–33. As such, future
studies in these usefulmodel organismsmay be pursued to determine
if mibefradil and L703606 will have a sensitizing effect on resistant
murine parasites in addition to validating the safety profile of such
combinations in a pre-clinical model.
While the screening process for novel chemosensitizers was found
to be both rapid (each screen of the LOPAC librarywas accomplished
within 15 hrs) and simple to perform (three steps: staining, washing
and taking readings), future work to further improve the screen
includes the development and use of a more highly-fluorescent
CQ molecule (to increase the resolution between high and low
a
Effect of chemosensitization on 11 parasite strains/isolates
0
50
100
150
200
250
300
350
400
450
500
3D
7
H
B3
7G
8
K1 D
d2
C
S2
T9
/9
4
SM
R
U
02
33
SM
R
U
02
72
SM
R
U
10
93
SM
R
U
11
16
C
Q
 IC
50
 (n
M
)
Veh
L703606 (132 nM)
Mibefradil (27 nM)
Desipramine (500 nM)
b
Relative effects of chemosensitization
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
3D
7
H
B
3
7G
8
K
1
D
d2
C
S
2
T9
/9
4
S
M
R
U
02
33
S
M
R
U
02
72
S
M
R
U
10
93
S
M
R
U
11
16
R
es
po
ns
e 
M
od
ifi
ca
tio
n 
In
de
x 
(R
M
I) Veh
L703606 (132 nM)
Mibefradil (27 nM)
Desipramine (500 nM)
Figure 4 | Effect of L703606, mibefradil and desipramine onmultiple lab strains and field isolates. (a) Chloroquine (CQ) IC50 in CQ-sensitive 3D7 and
HB3, CQ-intermediate resistant 7G8 and CQ-resistant K1, Dd2, CS2, T9/94, SMRU0233, SMRU0272, SMRU1093 and SMRU1116 parasites in the
presence of vehicle control (Veh), 132 nM of L703606, 27 nM of mibefradil or 500 nM of desipramine. P-values are in Supplementary Table 3 and show
that all three compounds are effective in reducing the respective IC50, but that mibefradil is less effective than desipramine in CS2, SMRU0233,
SMRU0272, SMRU1093 and SMRU1116. Figures show mean 6 SEM; n 5 3. (b) Response modification index shows the relative reduction of CQ IC50
between the untreated and treated cultures.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 1734 | DOI: 10.1038/srep01734 6
fluorescence levels and reduce false negatives) and the utilization of a
high-throughput flow cytometer (which has a greater sensitivity than
the plate reader). In addition, the development of a counter-screen
using a complimentary (non-overlapping) fluorophore-emission is
another possibility (so as to minimize the exclusion of true positives
that possess inherent blue fluorescences).
Notwithstanding, the identification of seven novel chemosensiti-
zers from the LOPAC library of 1280 compounds is now revealed.
Two of these hits possess greater potency than classical chemosensi-
tizers. Such results clearly demonstrate the usefulness of our assay in
the fight against malaria. In a high throughput context, extensive
screening campaigns of larger drug-like compound libraries are con-
ceivable. Such endeavours should help uncover a greater set of novel
chemosensitizers with suitable efficacy and safety profiles. Arguably,
in combination with CQ, this straightforward screening method has
the potential to return CQ to the arsenal of effective antimalarial
treatments in the clinic.
Methods
Parasite culture. The seven laboratory strains of P. falciparum, used include 3D7
(MRA-102), HB3 (MRA-155), 7G8 (MRA-154), K1 (MRA-159), CS2 (MRA-96),
Dd2 (MRA-156) and T9/94 (MRA-153), all of which were obtained from MR4,
ATCCHManassas Virginia. Four P. falciparum field isolates were collected from
malaria patients attending the clinics of the Shoklo Malaria Research Unit (SMRU)
Mae Sod region of Tak Province in the northwest of Thailand from January 2009 to
December 2010 and designated as SMRU0233, SMRU0272, SMRU1093 and
SMRU1116. All P. falciparum cultures were cultured continuously and synchronized
weekly as described previously18.
Preparation of drugs & library. CM-CQ was synthesized, stored and prepared as
described previously18.
All other drugs were purchased from Sigma-Aldrich including the Library of
Pharmacologically Active Compounds (LOPAC1280), chloroquine diphosphate
(CQ), (6)-verapamil hydrochloride (VPM), chlorpromazine hydrochloride (CPZ),
desipramine hydrochloride (DSP), promethazine hydrochloride (PMZ), (6)-chlor-
pheniramine maleate salt (CPR), (6)-propranolol hydrochloride (PPL),
(1)-cis-diltiazem hydrochloride (DTZ), cyproheptadine hydrochloride sesquihy-
drate, prochlorperazine dimaleate salt, cyclosporine A (CsA), loperamide hydro-
chloride, metergoline, L-765,314 hydrate (L765314), L-703,606 oxalate salt hydrate
(L703606), mibefradil dihydrochloride hydrate, methiothepin mesylate salt, octo-
clothepin maleate salt, tamoxifen citrate and xanthine amine congener.
CQ was dissolved in PBS at the beginning of each experiment and filter-sterilized
prior to use. All individually purchased compounds were dissolved in DMSO, stored
in aliquots at220uC and diluted to working concentrations with PBS. All compounds
were protected from light.
LOPAC compounds were provided in 96-well format and dissolved in 10 mM
DMSO. Working plates were made by dilution to 100 mM in PBS and immediately
aliquoted to experimental plates (i.e. experimental plates were pre-plated with
LOPAC compounds) which were stored at 220uC and thawed on the day of the
experiment.
CM-CQ staining. CM-CQ is a blue-fluorescent labeled CQ moiety that has close
resemblance to its parent CQmolecule as described previously18 . Parasite cultures at
2.5% hematocrit and between 7–12% parasitemia (late-ring stage 22–26 hrs post-
invasion) were incubated in a flat-bottom 96-well plate at a final staining
concentration of 6 mM of CM-CQ for 10 hrs in a perfused dark humidified
incubation chamber at 37uC. After which, cultures were resuspended in fresh PBS
using either a 12-channel (Eppendorf) or a 96-channel (VIAFLO-96) pipette. Cells
were then either diluted further for flow cytometry analysis using LSRII or transferred
to black flat-bottom 96-well plates and left to settle for 1 hr prior to fluorescence plate
measurements.
Hoechst staining. Hoechst 33342 (Invitrogen, Eugene, OR, USA) is a lipophilic
DNA-binding fluorescent stain that is excited by ultraviolet light (350 nm), and emits
a blue fluorescent signal (461 nm). Cultures at 1.25% to 2.5% hematocrit and varying
parasitemia and stages were stained with Hoechst at a final concentration of 1 mg/ml
for 30 min at 37uC. After which, cells were washed once with PBS prior to flow
cytometry (LSRII or Quanta).
8-point, 12-point and 96-point IC50. Parasitemia of each strain was determined by
flow cytometry and diluted with fresh RBC to 1% parasitemia and hematocrit
adjusted to 1.25% at the start of each IC50 assay. A 103 working solution of each drug
concentration wasmade on a separate plate and 20 ml was added per well. Plates were
Figure 5 | Schematic representation of the pharmacophore model developed by Bhattacharjee et al. and three CQ-resistance reversal agents with their
‘‘Best-Fit’’ Scores. (top); chemical structure of the seven novel chemosensitizers presented in this report (bottom).
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kept away from light and stored for 48 hrs at 37uC in a humidified and perfused
incubation chamber. After which, cells were stained with Hoechst and analyzed by
flow cytometry.
In most cases, a 12-point curve was used to derive an estimated IC50 value.
However, this was reduced to an 8-point curve for IC50 used in Fig. 3 due to the large
number of compounds at different concentrations being tested. Conversely, this was
expanded to a 96-point curve in Supplementary Figure 3 so as to accurately determine
the respective IC50 values in K1.
Flow cytometry. Cell numbers and fluorescence intensity was assayed using either
the BD LSRII Special Order System (BD, San Jose, CA, USA) or the Beckman Coulter
Cell LabQuanta SC, both of which are equipped with automated 96-well plate
samplers.
LSRII was used for CM-CQ and Hoechst-stained cells. Both were excited with a
355 nm UV laser while detection was by a 450LP 450/50BP filter (380 V). Forward
and side scatter was adjusted as described elsewhere19 and at least 100,000 erythro-
cytes were analyzed. In determining the proportion of CM-CQ parasites, Hoechst-
stained duplicate wells were used to determine parasitemia.
LabQuanta was used for Hoechst-stained parasites in IC50 assays only. Excitation
was through a 355/37 nm arc lamp while detection used a 550DLP 465BP filter.
Electronic voltage was adjusted to accommodate erythrocytes and to exclude debris.
Initial experiments were run simultaneously on both LSRII and LabQuanta to ensure
suitability of LabQuanta in IC50 determination. At least 50,000 erythrocytes were
analyzed from each sample.
Fluorescence plate measurements. After cells were stained with CM-CQ, washed
and transferred to black flat-bottom 96-well plates (NUNC), cells were allowed to
settle for 1 hr before measurements. Fluorescence measurements were taken with a
TECAN Infinite M200 plate reader (top-reading), with excitation at 350/9 nm,
emission at 500/20 nm, number of flashes default at 25 and integration time default at
20 ms.
When multiple strains were used (Fig. 1c & d), parasitemia between strains was
equilibrated by addition of uninfected erythrocytes prior to staining.
Statistics.All data shown are means 6 SEM. Statistical difference was analyzed using
ANOVA and post-hoc comparison using Tukey’s test. Significantly different results
(P , 0.05) were highlighted. IC50 curve-plotting was done using GraphPad Prism 5
(v5.04) using a four-parameter logistic curve (variable slope).
Ethics. The blood collection protocol for malaria in vitro culture was approved by the
Institutional Review Board (IRB) (NUS-IRB Reference Code: 11-383, Approval
Number: NUS-1475) of the National University of Singapore (NUS). Written
informed consent was obtained from all participants involved in the study.
The clinical field isolates used in this study were collected under the following
ethical guidelines in the approved protocols: OXTREC Reference Number 29-09
(Center for Clinical Vaccinology and Tropical Medicine, University of Oxford,
Oxford, United Kingdom).
Permission to use the field isolates for research within NUS was in accordance with
NUS IRB (Reference Code: 12-369E).
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